<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794208</url>
  </required_header>
  <id_info>
    <org_study_id>GEXGP24201</org_study_id>
    <nct_id>NCT01794208</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®</brief_title>
  <official_title>A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing ICSI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is the determination of the recommended standard treatment dose
      of FSH-GEX(TM) in women undergoing ICSI (intracytoplasmic sperm injection) treatment as
      assessed by follicle growth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of follicles</measure>
    <time_frame>day of hCG (human chorionic gonadotropin) injection; variable timeframe; up to 4 weeks treatment</time_frame>
    <description>The number of follicles on the day of hCG injection after stimulation with follicle stimulating hormone (FSH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic effect of FSH following administration by subcutaneous injection</measure>
    <time_frame>every second day up to HCG injection; variable timeframe; up to 4 weeks treatment</time_frame>
    <description>follicular response as determined by transvaginal ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of retrieved cumulus-oocyte-complexes</measure>
    <time_frame>at oocyte retrieval; up to 2 days after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of oocytes retrieved</measure>
    <time_frame>at oocyte retrieval; up to 2 days after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of two pronuclei oocytes</measure>
    <time_frame>one day after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical pregnancy rate</measure>
    <time_frame>14 to 20 days after last FSH dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of clinical pregnancy</measure>
    <time_frame>approx. 4 to 6 weeks after last FSH dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>approx. 4 - 6 weeks after last FSH dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic effect of FSH following administration by subcutaneous injection</measure>
    <time_frame>every second day up to HCG injection; variable timeframe; up to 4 weeks treatment</time_frame>
    <description>Estradiol and inhibin B serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate and live birth rate</measure>
    <time_frame>post-study observation period of 9 months after hCG stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability</measure>
    <time_frame>up to 4 to 6 weeks after last FSH dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH-GEX(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH-GEX(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH-GEX(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH-GEX(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH-GEX(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gonal-f(R)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-GEX(TM)</intervention_name>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_label>treatment 3</arm_group_label>
    <arm_group_label>treatment 4</arm_group_label>
    <arm_group_label>treatment 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-f(R)</intervention_name>
    <arm_group_label>treatment 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient for whom ICSI treatment is justified

          -  serum follicle-stimulating hormone concentration

          -  Anti-mullerian hormone concentration

          -  Antral follicle count

          -  Body mass index and body weight

          -  Presence of both ovaries

          -  Regular spontaneous cycles between 21 and 35 days in length

          -  Normal uterine cavity as assessed by transvaginal sonography at Screening

          -  Willing and able to comply with the protocol

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Patients who had more than two unsuccessful previous assisted reproduction technology
             cycles before inclusion into the study

          -  Previous poor responders

          -  Patients with previous hyperstimulation syndrome or cycle cancellation because of
             imminent hyperstimulation syndrome

          -  Patients with a history of or current polycystic ovarian morphology syndrome

          -  Patients with a history of or current endometriosis III or IV

          -  Presence of ovarian cyst at Screening

          -  Any contraindication to becoming pregnant

          -  History of ≥ 3 clinical or preclinical miscarriages

          -  abnormal cervical smear, Papanicolaou [PAP] score ≥ 3

          -  Any history of malignant cancer other than in situ breast or skin cancer requiring
             local excision

          -  Any endocrine abnormalities requiring treatment

          -  Any clinically significant systematic disease

          -  Any known infection with human immunodeficiency virus, hepatitis B or C

          -  History of thrombosis or other risk factors including any coagulation abnormality
             leading to an increased risk of clotting

          -  Family history of genetic risk factors concerning pregnancy or birth

          -  Use of concomitant medication, which in the opinion of the investigator might
             interfere with ICSI preparation procedures

          -  Active smoking

          -  Any active substance abuse of drugs, medications or alcohol within the last five years

          -  Patients in an institution by official or court order

          -  Patients who are unable or unwilling to provide informed consent

          -  Any participation in another clinical trial within the last 60 days before
             randomisation

          -  Previous FSH-GEX™ administration.

          -  Known hypersensitivity to any component of the investigational and non investigational
             products used in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>study director</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-vitro fertilization</keyword>
  <keyword>reproductive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

